Impact of PSMA-Targeted Imaging Modalities on Management of Prostate Cancer

The panel reviews clinical data and provides real-world insight on how use of PSMA-PET imaging has impacted the management of patients with prostate cancer.

EP: 1.Risk Stratification of Patients with Prostate Cancer

EP: 2.Conventional Imaging for Prostate Cancer

EP: 3.Introduction to PSMA-Targeted PET Imaging

EP: 4.Approved PSMA-PET Imaging Tracer Options for Prostate Cancer

EP: 5.Practical Considerations for Selection of PSMA-PET Tracers

Now Viewing

EP: 6.Impact of PSMA-Targeted Imaging Modalities on Management of Prostate Cancer

EP: 7.Overview of Available Clinical Guidelines on PSMA-PET Imaging in Prostate Cancer

EP: 8.Challenges of Implementing PSMA-Targeted PET Imaging in Prostate Cancer

EP: 9.Navigating and Overcoming Challenges of PSMA-PET Imaging Results Interpretation

EP: 10.Best Practices for Communication: A Multidisciplinary Perspective

EP: 11.Navigating Virtual Tumor Boards for Prostate Cancer PSMA-PET Imaging

EP: 12.Unmet Needs in Imaging for Patients With Prostate Cancer

EP: 13.PSMA-Based Imaging and Theranostics: A Summary of Current Paradigm Shifts and a Look to the Future

EP: 14.Closing Thoughts on the Impact of PSMA-PET Imaging in Prostate Cancer

Related Videos

Related Content

Advertisement

January 23rd 2025

Health-related QOL is comparable among ARPI regimens for CSPC

Hannah Clarke

At 25 weeks, FACT-P total score remained comparable between the arms.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 13th 2025

FDA accepts NDA for 3-month leuprolide mesylate formulation for advanced prostate cancer

Hannah Clarke

The PDUFA target action date has been set for August 29, 2025.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 7th 2025

Expanded indication sought for darolutamide in mHSPC in China

Hannah Clarke

The application is supported by data from the pivotal phase 3 ARANOTE trial.

January 1st 2025

2024 Urology Times pipeline report

Jason M. Broderick Hannah Clarke Brittany Lovely

Catch up on all the notable drug and device approvals in urology over the past year.

Related Content

Advertisement

January 23rd 2025

Health-related QOL is comparable among ARPI regimens for CSPC

Hannah Clarke

At 25 weeks, FACT-P total score remained comparable between the arms.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 13th 2025

FDA accepts NDA for 3-month leuprolide mesylate formulation for advanced prostate cancer

Hannah Clarke

The PDUFA target action date has been set for August 29, 2025.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 7th 2025

Expanded indication sought for darolutamide in mHSPC in China

Hannah Clarke

The application is supported by data from the pivotal phase 3 ARANOTE trial.

January 1st 2025

2024 Urology Times pipeline report

Jason M. Broderick Hannah Clarke Brittany Lovely

Catch up on all the notable drug and device approvals in urology over the past year.